Pulmonary HypertensionNCT04224012
Effect of Exercise and Respiratory Therapy on Right Ventricular Function in Severe Pulmonary Hypertension
A study testing Exercise and respiratory therapy in people with Pulmonary Hypertension, run by Heidelberg University at 1 site in Germany.
Trial summary
Chronic pulmonary hypertension (PH) is associated with impaired exercise capacity, quality of life and right ventricular function.The disease is characterized by an increase of pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart insufficiency. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pulmonary Hypertension
- What is being tested?
- Exercise and respiratory therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 96 participants
- Where
- 1 siteGermany
- Study dates
- Aug 2015to Aug 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Consent form
- Men and women >18 years
- Symptomatic PH (WHO-FC II-IV) invasive diagnostis with right heart catheterization: mPAP >25mmHg and a stable optimized treatment for at least 2 month
- Ptients who are able to understand and agree to participate in the study
Who cannot join
- Pregnancy or breast feeding
- Variation in the medication during the last 2 months
- Patients with signs of right heart decompensation
- Major walking problems
- Unclear diagnosis
- No invasive clarification of the PH
Show all 9Show fewer
- Acute illness, infections and fever
- Grave lung disease with FEV1 <50% or TLC <70% from target
- Further conclusion criteria are followed: acrive myokarditis, unstable angina pectoris, movement induced venr´tricular rhythmdisturbance, decompensation of the right hart insufficiency, meaningful heartvitien, hyperthrophic obstructive cardiomyopathie or a high grade reduced left ventricular pumpu function
Trial locations and contacts
1 site in 1 country.
Germany1 site, 1 recruiting
- Recruiting
Centre for Pulmonary Hypertension at the Thoraxklinik, Heidelberg University Hospital
Heidelberg, 69126
Ekkehard Grünig, MD, +496221396 ext. 8053, ekkehard.gruenig@med.uni-heidelberg.de
Ekkehard Grünig, MD
About this study
Chronic pulmonary hypertension (PH) is associated with impaired exercise capacity, quality of life and right ventricular function.The disease is characterized by an increase of pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart insufficiency. In later stages of the disease, the right heart is not able to further increase right ventricular contractility (cardiac index) during exercise. Within the last decade, new disease-targeted medical therapies have been approved for treatment of pulmonary arterial hypertension (PAH). Sequential and upfront combinations of these agents have shown to further improve symptoms, 6-minute walking distance (6-MWD) and hemodynamics in PAH patients.
Previous training studies have suggested that exercise training as add-on to medical treatment is highly effective improving exercise capacity, quality of life and symptoms. Prospective studies with a 24±12 months follow-up period suggested that exercise training may also improve the rate of clinical worsening events as the need for hospitalization, additional PH-medication, lung-transplantation and death.
Read more
There is also first data that exercise training may have a positive impact on the right ventricular function.
This randomised controlled study aims to assess whether exercise training
Read the detailed description
The aim of this prospective, randomized, controlled study in patients with pulmonary hypertension, who are under stable optimized treatment for at least 2 months, is to examine the effect of an additional exercise and respiratory therapy on the right heart function.
The primary endpoint of this study is the right heart function, measured by cardiac index during exercise invasively determined by right heart catheterization. More hemodynamic parameters for the determination of the right heart function as well as clinical and molecular parameters are relevant to record the physiological effect of the training. The molecular parameters are composed of laboratory parameter and inflammatory parameter as well as genetic analyses, measurements of epigenetic changes measured by microRNA Expressions and DNA-methylation and imunohistochemical measurements of the quadriceps musculature.
The study parameters will be assessed in the patient's routine examinations. Clinical parameters comprise of hemodynamic assessment of pulmonary arterial pressure during exercise, pump function of left and right ventricle, and further echocardiographic parameters. Improvement of exercise capacity will be measured by the change of six-minute walking distance, the breathing economics, the world health organization functional class (WHO functional class), peak oxygen consumption and blood gas analysis. The quality of life will be assessedwith the SF-36 questionnaire.Data for survival analysis will be gained by structured phone interviews . The safety of the training is warranted by long-term, rest- and stress-ECG, safety laboratory, systemic blood pressure, heart frequency, oxygen saturation and occurrence of adverse events. In addition to the routine examinations at baseline and after 15 weeks, a right heart catheterization will be performed.
Patients will be examined in the Thoraxklinik Heidelberg. Patients of the training group will take part in a specific, 3-week inpatient training program at the rehabilitation center Königstuhl Heidelberg right after the baseline examination. The training program consists of exercise and respiratory therapy as well as a mental gait training. Respiratory therapy will be performed 5 times/week for 30 minutes. Furthermore, 15-25 minutes low dosed interval training on a bicycle ergometer, dumbbell training of particular muscle groups with low weights and supervised walks on ground-level will be scheduled 5-7 times/week. Three- to five times a week a "mental gait training" is conducted to estimate the patient's individual physical abilities and limitations. The heart rate during exerciseand the intensity of the training will be closely monitored and individually adjusted. After three weeks of in-hospital rehabilitation the patients are asked to continue the training for twelve further weeks at home. All patients will be examined before the training program, at the end of the in-hospital phase after three weeks and after 15 weeks. Patients of the control group will continue with their lifestyle without individual training prescriptions. After having participated in the study, patients of the control group will also be offered to take part in the training program.
The control examinations cover the medical history, WHO functional class, physical examination, ECG, echocardiography at rest and during exercise, spiroergometry, quality of life, blood-gas analysis, lung function, 6-minute walking distance, oxygen saturation, blood pressure and heart rate, laboratory tests. An optional magnet resonance imaging at the beginning and after three months may also be conducted. At baseline, an optional genetic assessment will be performed; and at the beginning, after three and 15 weeks the expression levels of micro RNA and methylation of the DNA will be assessed. A biopsy of the quadriceps musculature will optionally be carried out at baseline and after 15 weeks. Medication will remain stable throughout the study.
- Conditions
- Pulmonary Hypertension
- Being tested
- Exercise and respiratory therapy
- Medical subject headings
- Hypertension, Pulmonary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exercise and respiratory therapyOther
Three weeks in-Hospital Rehabilitation program with continuation of exercise Training at home
| Study group | Role | What they receive |
|---|---|---|
| Conventional therapy group (control group) | No intervention | patients of the control Group receive usual care |
| Interventional group (training group) | Experimental | Specialized exercise and respiratory therapy for patients with pulmonary hypertension Receives: Other: Exercise and respiratory therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiac index during exercise, right heart catheter
measured by right heart catheterisation; Training vs. control group
Measured: Change form baseline to final assessment after 15 weeks
Secondary outcomes (19)
Cardiac index at rest, right heart catheter
right heart catheterization cardiac index at rest
Measured: Change form baseline to final assessment after 15 weeks
Pulmonary vascular resistance at rest, right heart catheter
right heart catheterization pulmonary vascular resistance at rest
Measured: Change form baseline to final assessment after 15 weeks
6-minute Walking distance
Physical exercise capacity, Walking distance in metres
Measured: Change form baseline to final assessment after 15 weeks
Peak oxygen consumption, cardiopulmonary exercise testing
cardiopulmonary exercise testing
Measured: Change form baseline to final assessment after 15 weeks
Peak Workload in Watts, achieved during cardiopulmonary exercise testing
cardiopulmonary exercise testing
Measured: Change form baseline to final assessment after 15 weeks
Peak respiratory equivalent during cardiopulmonary exercise testing
cardiopulmonary exercise testing
Measured: Change form baseline to final assessment after 15 weeks
Epigenetic changes of micro RNA
Epigenetic changes of the microRNA and the state of methylization (muscle biopsy of the quadrizeps muscuation and peripheral blood)
Measured: Change form baseline to final assessment after 15 weeks
right atrial area, assessed by echocardiography
Echocardiography
Measured: Change form baseline to final assessment after 15 weeks
right ventricular area, assessed by echocardiography
Echocardiography
Measured: Change form baseline to final assessment after 15 weeks
right ventricular pump function, qualitative during echocardiography
Echocardiography
Measured: Change form baseline to final assessment after 15 weeks
tricuspid annular plane systolic excursion, echocardiography
Echocardiography
Measured: Change form baseline to final assessment after 15 weeks
Physical Summation score, SF-36
Quality of life by short form health Survey 36 (SF-36); values from 0-100 (higher value = better outcome)
Measured: Change form baseline to final assessment after 15 weeks
Mental Summation score, SF-36
Quality of life by short form health Survey 36 (SF-36)values from 0-100 (higher value = better outcome)
Measured: Change form baseline to final assessment after 15 weeks
World Health Organization functional class
symptoms of pulmonary hypertension
Measured: Change form baseline to final assessment after 15 weeks
Laboratory: Levels of N-terminal pro brain natriuretic peptide (NT-proBNP)
marker of the right heart strain
Measured: Change form baseline to final assessment after 15 weeks
Oxygen Saturation, blood gas analysis
Blood gas analysis
Measured: Change form baseline to final assessment after 15 weeks
Right heart size, assessed by magnetic resonance tomography
magnetic resonance tomography
Measured: Change form baseline to final assessment after 15 weeks
Right heart function, qualitative, assessed by magnetic resonance tomography
magnetic resonance tomography
Measured: Change form baseline to final assessment after 15 weeks
Clinical worsening, frequency of clinical worsening and adverse Events during the study period
frequency of clinical worsening events
Measured: assessed form baseline to final assessment after 15 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2020
- Study startAug 2015
- Primary completionAug 2024 (estimated)
- Study completionAug 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 96 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Heidelberg University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Dr. med. Ekkehard Gruenig, Heidelberg University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04224012
- Sponsor's protocol ID
- TRAIN-01
- Status last verified
- Jul 2022
- First submitted
- 19 Dec 2019
- Last updated
- 14 Jul 2022
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Exercise and Respiratory Therapy on Right Ventricular Function in Severe Pulmonary Hypertension
- ClinicalTrials.gov ID
- NCT04224012
- Acronym / sponsor ID
- TRAIN-01
- Conditions
- Pulmonary Hypertension
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 96 participants (estimated)
- Lead sponsor
- Heidelberg UniversityUniversity, hospital or other
- Study start
- Aug 2015
- Primary completion
- Aug 2024 (estimated)
- Study completion
- Aug 2024 (estimated)
- First posted
- 13 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic pulmonary hypertension (PH) is associated with impaired exercise capacity, quality of life and right ventricular function.The disease is characterized by an increase of pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart insufficiency. In later stages of the disease, the right heart is not able to further increase right ventricular contractility (cardiac index) during exercise. Within the last decade, new disease-targeted medical therapies have been approved for treatment of pulmonary arterial hypertension (PAH). Sequential and upfront combinations of these agents have shown to further improve symptoms, 6-minute walking distance (6-MWD) and hemodynamics in PAH patients.
Previous training studies have suggested that exercise training as add-on to medical treatment is highly effective improving exercise capacity, quality of life and symptoms. Prospective studies with a 24±12 months follow-up period suggested that exercise training may also improve the rate of clinical worsening events as the need for hospitalization, additional PH-medication, lung-transplantation and death.
There is also first data that exercise training may have a positive impact on the right ventricular function.
This randomised controlled study aims to assess whether exercise training
Detailed description
The aim of this prospective, randomized, controlled study in patients with pulmonary hypertension, who are under stable optimized treatment for at least 2 months, is to examine the effect of an additional exercise and respiratory therapy on the right heart function.
The primary endpoint of this study is the right heart function, measured by cardiac index during exercise invasively determined by right heart catheterization. More hemodynamic parameters for the determination of the right heart function as well as clinical and molecular parameters are relevant to record the physiological effect of the training. The molecular parameters are composed of laboratory parameter and inflammatory parameter as well as genetic analyses, measurements of epigenetic changes measured by microRNA Expressions and DNA-methylation and imunohistochemical measurements of the quadriceps musculature.
The study parameters will be assessed in the patient's routine examinations. Clinical parameters comprise of hemodynamic assessment of pulmonary arterial pressure during exercise, pump function of left and right ventricle, and further echocardiographic parameters. Improvement of exercise capacity will be measured by the change of six-minute walking distance, the breathing economics, the world health organization functional class (WHO functional class), peak oxygen consumption and blood gas analysis. The quality of life will be assessedwith the SF-36 questionnaire.Data for survival analysis will be gained by structured phone interviews . The safety of the training is warranted by long-term, rest- and stress-ECG, safety laboratory, systemic blood pressure, heart frequency, oxygen saturation and occurrence of adverse events. In addition to the routine examinations at baseline and after 15 weeks, a right heart catheterization will be performed.
Patients will be examined in the Thoraxklinik Heidelberg. Patients of the training group will take part in a specific, 3-week inpatient training program at the rehabilitation center Königstuhl Heidelberg right after the baseline examination. The training program consists of exercise and respiratory therapy as well as a mental gait training. Respiratory therapy will be performed 5 times/week for 30 minutes. Furthermore, 15-25 minutes low dosed interval training on a bicycle ergometer, dumbbell training of particular muscle groups with low weights and supervised walks on ground-level will be scheduled 5-7 times/week. Three- to five times a week a "mental gait training" is conducted to estimate the patient's individual physical abilities and limitations. The heart rate during exerciseand the intensity of the training will be closely monitored and individually adjusted. After three weeks of in-hospital rehabilitation the patients are asked to continue the training for twelve further weeks at home. All patients will be examined before the training program, at the end of the in-hospital phase after three weeks and after 15 weeks. Patients of the control group will continue with their lifestyle without individual training prescriptions. After having participated in the study, patients of the control group will also be offered to take part in the training program.
The control examinations cover the medical history, WHO functional class, physical examination, ECG, echocardiography at rest and during exercise, spiroergometry, quality of life, blood-gas analysis, lung function, 6-minute walking distance, oxygen saturation, blood pressure and heart rate, laboratory tests. An optional magnet resonance imaging at the beginning and after three months may also be conducted. At baseline, an optional genetic assessment will be performed; and at the beginning, after three and 15 weeks the expression levels of micro RNA and methylation of the DNA will be assessed. A biopsy of the quadriceps musculature will optionally be carried out at baseline and after 15 weeks. Medication will remain stable throughout the study.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Conventional therapy group (control group) | No intervention | –patients of the control Group receive usual care |
| Interventional group (training group) | Experimental | Other: Exercise and respiratory therapySpecialized exercise and respiratory therapy for patients with pulmonary hypertension |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Consent form
- Men and women >18 years
- Symptomatic PH (WHO-FC II-IV) invasive diagnostis with right heart catheterization: mPAP >25mmHg and a stable optimized treatment for at least 2 month
- Ptients who are able to understand and agree to participate in the study
Key exclusion criteria (9 listed)
- Pregnancy or breast feeding
- Variation in the medication during the last 2 months
- Patients with signs of right heart decompensation
- Major walking problems
- Unclear diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exercise and respiratory therapyThree weeks in-Hospital Rehabilitation program with continuation of exercise Training at home | Other | Interventional group (training group) |
Primary outcome
Cardiac index during exercise, right heart catheter
Time frame: Change form baseline to final assessment after 15 weeks
measured by right heart catheterisation; Training vs. control group
19 secondary outcomes
Cardiac index at rest, right heart catheter
Time frame: Change form baseline to final assessment after 15 weeks
Pulmonary vascular resistance at rest, right heart catheter
Time frame: Change form baseline to final assessment after 15 weeks
6-minute Walking distance
Time frame: Change form baseline to final assessment after 15 weeks
Peak oxygen consumption, cardiopulmonary exercise testing
Time frame: Change form baseline to final assessment after 15 weeks
Peak Workload in Watts, achieved during cardiopulmonary exercise testing
Time frame: Change form baseline to final assessment after 15 weeks
Peak respiratory equivalent during cardiopulmonary exercise testing
Time frame: Change form baseline to final assessment after 15 weeks
Epigenetic changes of micro RNA
Time frame: Change form baseline to final assessment after 15 weeks
right atrial area, assessed by echocardiography
Time frame: Change form baseline to final assessment after 15 weeks
right ventricular area, assessed by echocardiography
Time frame: Change form baseline to final assessment after 15 weeks
right ventricular pump function, qualitative during echocardiography
Time frame: Change form baseline to final assessment after 15 weeks
tricuspid annular plane systolic excursion, echocardiography
Time frame: Change form baseline to final assessment after 15 weeks
Physical Summation score, SF-36
Time frame: Change form baseline to final assessment after 15 weeks
Mental Summation score, SF-36
Time frame: Change form baseline to final assessment after 15 weeks
World Health Organization functional class
Time frame: Change form baseline to final assessment after 15 weeks
Laboratory: Levels of N-terminal pro brain natriuretic peptide (NT-proBNP)
Time frame: Change form baseline to final assessment after 15 weeks
Oxygen Saturation, blood gas analysis
Time frame: Change form baseline to final assessment after 15 weeks
Right heart size, assessed by magnetic resonance tomography
Time frame: Change form baseline to final assessment after 15 weeks
Right heart function, qualitative, assessed by magnetic resonance tomography
Time frame: Change form baseline to final assessment after 15 weeks
Clinical worsening, frequency of clinical worsening and adverse Events during the study period
Time frame: assessed form baseline to final assessment after 15 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2022.
Related trials for Pulmonary Hypertension
RecruitingObservational study
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Asthma Bronchial
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
RecruitingPhase 2
Spironolactone for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
RecruitingPhase 1/2
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Pulmonary Arterial Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Centre for Pulmonary Hypertension at the Thoraxklinik, Heidelberg University Hospital
Heidelberg, Germany
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise and respiratory therapy in people with Pulmonary Hypertension, run by Heidelberg University at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cardiac index during exercise, right heart catheter (time frame: Change form baseline to final assessment after 15 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2022.